Various studies have confirmed the adverse extrapolative role of low PTEN/high p-AKT/high PI3K expression in patients with RCC, which establishes the potential clinical consequence of the PI3K/AKT pathway. This evidence concerns the gene AKT1 and renal cell carcinoma.